Developmental Research program (DRP)

The principal goal of the Developmental Research Program is to fund promising early stage projects that address important translational objectives in prevention, early detection, and therapy of pancreatic carcinoma. Our principal intent for the Developmental Research Program is to bring novel translational research projects to the SPORE program. Key elements that determine priority in this program are innovation, novelty, and potential for success in translational pancreatic cancer research. All Developmental Funds will be awarded by competition based on submission of a NIH-style pilot project application. There is a requirement for clear evidence that the proposed project shows potential of developing into a larger research project that will involve human intervention for pancreatic cancer (diagnostic or therapeutic). 

PI Title
 Eight projects were funded in 2013:
 Michael Brattain, PhD and Quan Ly, MD  Novel strategies in pancreatic cancer treatment
 Kaustubh Datta, PhD  Effects of Zoledronic Acid on Pancreatic Tumor Cells
 Chittibabu (Babu) Guda, PhD  Identification and characterization of pancreatic cancer subtypes using exome-sequencing data
 Michael Hollingsworth, PhD  Inhibition of CDK5 as a Treatment for Pancreatic Cancer (year three)
 Ram Mahato, PhD  Polymeric Nanomedicines for Co-Delivery of Gemcitabine and miRNA
 Angie Rizzino, PhD  Effects of Zoledronic Acid on Pancreatic Tumor Cells
 Polina Shcherbakova, PhD  DNA Polymerase d and ε Mutations in Pancreatic Cancer
 Joyce Solheim, PhD  Optimizing Production of the Therapeutic Chemokine CCL21
Eight projects were funded for 2011-2012:   
Michael Brattain, PhD & Quan Ly, MD Pre-clinical Development of Novel Therapies for Pancreatic Cancer  (Year 2)
Michael A. Hollingsworth, PhD Inhibition of CDK5 as a treatment for pancreatic cancer (Year 2)
Amar Natarajan, PhD Define the disease state of IKKb and develop small molecule inhibitors against it for  pancreatic cancer therapy 
Angie Rizzino, PhD The Roles of the Deubiquitinating Enzyme USP9X in Pancreatic Cancer
Polina Shcherbakova, PhD Prevalence of DNA Polymerase δ Mutations in Colorectal Cancer
Simon Sherman, PhD Prognostic Tools for Pancreatic Cancer Survival 
Pankaj Singh, PhD A metabolic approach for targeting gemcitabine resistance in pancreatic cancer 
Jenny Wang, PhD Unique Role of HIF1α in Colon Cancer Metastasis
Five projects were funded in response to the 2010 DRP RFA:
 Michael Brattain, PhD Pre-clinical Development of Novel Therapies for Pancreatic Cancer 
 David Berkowitz, PhD (UNL) A Novel Podophyllum Lignan-based Approach to Therapeutics for Pancreatic Cancer
 Michael A. Hollingsworth, PhD Inhibition of CDK5 as a treatment for pancreatic cancer
 Joyce Solheim, PhD Strategies to Decrease Immune Evasion and Growth of Pancreatic Cancer Cells 
 Vimla Band, PhD Ecd as a regulator of cell cycle and pancreatic oncogenesis 

 

;